<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02683083</url>
  </required_header>
  <id_info>
    <org_study_id>CAM-VHH1</org_study_id>
    <secondary_id>2015-004840-21</secondary_id>
    <nct_id>NCT02683083</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients</brief_title>
  <acronym>CAM-VHH1</acronym>
  <official_title>Phase I Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients: CAM-VHH1 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Camel-IDS NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Camel-IDS NV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary purpose of the clinical study is to evaluate the safety, biodistribution and
      radiation dosimetry of [131I]-SGMIB Anti-HER2 VHH1 in healthy volunteers and patients with
      HER2+ breast cancer.

      Secondary purpose of the clinical study is to evaluate the tumor uptake of [131I]-SGMIB
      Anti-HER2 VHH1 in patients with HER2+ breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">February 5, 2018</completion_date>
  <primary_completion_date type="Actual">February 5, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Tumor Targeting Potential Will be Visually Scored on the Planar Total Body Scan</measure>
    <time_frame>1 day</time_frame>
    <description>Cancer lesions above 3 cm will be visually interpreted by an experienced nuclear medicine physician. Lesions will be scored positive if CAM-H2 uptake in the lesion is higher than surrounding background.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>[131I]-SGMIB Anti-HER2 VHH1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>[131I]-SGMIB Anti-HER2 VHH1</intervention_name>
    <arm_group_label>[131I]-SGMIB Anti-HER2 VHH1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects will only be included in the study if they meet all of the following criteria:

          -  Subjects who have given informed consent

          -  Subjects that agree not to drink alcoholic beverages or use any drugs during the study

          -  Subject with blood parameters within normal ranges

          -  Age: at least 18 years old

        Patients will only be included in the study if they meet all of the following criteria:

          -  Patients who have given informed consent

          -  Patients that agree not to drink alcoholic beverages or use any drugs during the study

          -  Age: at least 18 years old

          -  Patients with local, locally advanced or metastatic HER2+ breast carcinoma as
             diagnosed on biopsied tissue by immunohistochemistry or fluorescence in situ
             hybridization (FISH).

        Exclusion Criteria:

        Patients will not be included in the study if one of the following criteria applies:

          -  Pregnant patients

          -  Breast feeding patients

          -  Patients with occupational exposure to ionizing irradiation

          -  Patients with previous thyroid disorders

          -  Patients that received radiolabeled compounds with a long half-life (&gt;7h) for
             diagnostic or therapeutic purposes within the last 2 days.

          -  Patients with absolute contra-indications for thyroid blockage with potassium iodide.

          -  Patients with abnormal liver: ALT/AST &gt; 2 times normal values; bilirubin &gt; 1.5 time
             normal values.

          -  Patients with abnormal kidney function: &lt; 50 ml/min/1,73 m2

          -  Patients with recent (&lt; 1 week) gastrointestinal disorders (CTCAE v4.0 grade 3 or 4)
             with diarrhea as major symptom

          -  Patients with any serious active infection

          -  Patients who have any other life-threatening illness or organ system dysfunction,
             which in the opinion of the investigator would either compromise patient safety or
             interfere with the evaluation of the safety of the test radiopharmaceutical

          -  Patients who cannot communicate reliably with the investigator

          -  Patients who are unlikely to cooperate with the requirements of the study

          -  Patients at increased risk of death from a pre-existing concurrent illness

          -  Patients who participated already in this study

          -  Patients who participated in a previous trial with Anti-HER2 VHH1

        Subjects will not be included in the study if one of the following criteria applies:

          -  Pregnant subjects

          -  Breast feeding subjects

          -  Subjects with occupational exposure to ionizing irradiation

          -  Subjects with clinical significant disease or on concomitant therapy (except
             contraception)

          -  Subjects with previous thyroid disorders

          -  Subjects that received radiolabeled compounds with a long half-life (&gt;7h) for
             diagnostic or therapeutic purposes within the last 2 days.

          -  Subjects with absolute contra-indications for thyroid blockage with potassium iodide.

          -  Subjects with abnormal liver: ALT/AST &gt; 2 times normal values; bilirubin &gt; 1.5 time
             normal values.

          -  Subjects with abnormal kidney function: &lt; 50 ml/min/1,73 m2

          -  Subjects with recent (&lt; 1 week) gastrointestinal disorders (CTCAE v4.0 grade 3 or 4)
             with diarrhea as major symptom

          -  Subjects with any serious active infection

          -  Subjects who have any other life-threatening illness or organ system dysfunction,
             which in the opinion of the investigator would either compromise subject safety or
             interfere with the evaluation of the safety of the test radiopharmaceutical

          -  Subjects who cannot communicate reliably with the investigator

          -  Subjects who are unlikely to cooperate with the requirements of the study

          -  Subjects at increased risk of death from a pre-existing concurrent illness

          -  Subjects who participated already in this study

          -  Subjects who participated in a previous trial with Anti-HER2 VHH1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <state>Choose A State</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <results_first_submitted>January 10, 2019</results_first_submitted>
  <results_first_submitted_qc>May 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 18, 2019</results_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 4, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT02683083/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>[131I]-SGMIB Anti-HER2 VHH1</title>
          <description>All subjects received one single intravenous injection of the investigational medical product ([131I]-SGMIB Anti-HER2 VHH1).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>[131I]-SGMIB Anti-HER2 VHH1</title>
          <description>All subjects received one single intravenous injection of the investigational medical product ([131I]-SGMIB Anti-HER2 VHH1).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.78" spread="18.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0</title>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[131I]-SGMIB Anti-HER2 VHH1</title>
            <description>All subjects received one single intravenous injection of the investigational medical product ([131I]-SGMIB Anti-HER2 VHH1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Tumor Targeting Potential Will be Visually Scored on the Planar Total Body Scan</title>
        <description>Cancer lesions above 3 cm will be visually interpreted by an experienced nuclear medicine physician. Lesions will be scored positive if CAM-H2 uptake in the lesion is higher than surrounding background.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>[131I]-SGMIB Anti-HER2 VHH1</title>
            <description>All subjects received one single intravenous injection of the investigational medical product ([131I]-SGMIB Anti-HER2 VHH1).</description>
          </group>
        </group_list>
        <measure>
          <title>The Tumor Targeting Potential Will be Visually Scored on the Planar Total Body Scan</title>
          <description>Cancer lesions above 3 cm will be visually interpreted by an experienced nuclear medicine physician. Lesions will be scored positive if CAM-H2 uptake in the lesion is higher than surrounding background.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>[131I]-SGMIB Anti-HER2 VHH1</title>
          <description>All subjects received one single intravenous injection of the investigational medical product ([131I]-SGMIB Anti-HER2 VHH1).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Adhesive plaster sensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tony Lahoutte</name_or_title>
      <organization>Camel-IDS</organization>
      <phone>0032 24799360</phone>
      <email>tony.lahoutte@camel-ids.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

